evipedia.aidev
← Back to Review

Audit: QRS - Selank for Health & Longevity

Audit conducted on 02/07/2026 02:27 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 86
Failed 0
N/A 5
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All benefits, risks, contraindications, interactions, protocol, monitoring, and qualitative items trace to the ER.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Speculative tiers and “theoretical” framing preserved (e.g., at-a-glance “remains theoretical”).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications and cautions carry the ER’s strength verbatim.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications from ER “Populations who should avoid”, interactions from ER interactions; no cross-category relabeling.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No citations, PMIDs, or names introduced in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Cautious, evidence-forward tone matches the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Expert yet accessible framing throughout.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not directives.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No prescriptive advice; footer disclaims medical advice.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information-presenting register used throughout.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain-language phrasing used; technical terms expanded where they appear.
2.8 Information is presented in a concise and very compact manner 🟢 Compact cells, gates, and tiers.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing targets the optimization audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/cycling/sourcing detail assumes a willing, proactive audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not written for the general population.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the optimization audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” phrasing; longevity framing used.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Formal terminology (e.g., “intranasal”, “adverse effects”) used throughout.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified (card/section headings, gate headings, tier labels, Monitoring column headers). 🟢 “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tier labels, and “Marker/Target/Why” all intact.
3.2 All “…” from the [qrs_template] are present in the QRS. 🟢 All template spans present; repeatable marker_#/qualitative_item_# patterns correctly instantiated.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Unaddressed spans (e.g., hidden high/medium placeholders) left unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. 🟢 No empty ER sections require empty-state phrasing; unused tiers hidden.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Contraindication/interaction and benefit/risk labels match ER wording.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels preserved from the ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators in the QRS body.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to fit a single page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is the first element after the doctype (lines 2–13).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by “—” at lines 3 and 12.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values are clean and unquoted.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: selank_2026-0702-0134_Opus_ER.md (line 4).
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.5.18 (line 5).
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” 🟢 qrs_creation_date: 2026-0702-0134 (line 6).
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus (line 7).
5.9 The nickname of the AI is just a single word model name without version, etc. 🟢 “Opus” is a single word without version.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8 (line 8).
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier 🟢 “Opus 4.8” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: selank_2026-0702-0134_Opus_QRS.html (line 9).
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values clean and correctly unquoted.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. 🟢 “Selank for Health & Longevity - Quick Reference Sheet” (line 21).
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. 🟢 “Selank for Health & Longevity” (line 416).
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 “07/02/2026” (line 420) matches 2026-0702.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8” (line 424).
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only title and subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Distills the ER Conclusion (lines 391–395).
7.2 [at_a_glance] is no longer than 60 words 🟢 58 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Russia/2009, non-sedating, focus/mood/stress, unreplicated Russian data, theoretical longevity, product quality all trace to ER.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain-language wording; no specialist acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics cited.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Drawn from the ER “Populations who should avoid Selank” bullet (line 259).
8.2 [stop_items] represent the Contraindications from the ER 🟢 Four populations match the ER.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item wrapped in <li> (lines 540–543).
8.4 Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details. No content after an em/en/hyphen dash. 🟢 Concise facts; no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet are preserved as part of the item, kept as concise as possible. 🟢 No parenthetical qualifiers in the ER contraindication items to preserve.
8.6 When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. 🟢 No ranking notation present.
8.7 If no [stop_items] are present the section is left empty N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Drawn from the ER interactions bullets (lines 247–257).
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Six interaction items, none duplicating contraindications.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item wrapped in <li> (lines 549–554).
9.4 Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details. No content after an em/en/hyphen dash. 🟢 Concise; mechanistic detail stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, etc. — are preserved as part of the item, kept concise. 🟢 Example drug lists preserved (e.g., benzodiazepines, Z-drugs, SSRIs).
9.6 When the ER uses ranking notation inside parens, normalize to a plain comma-separated list. 🟢 No ranking notation present.
9.7 If no [caution_items] are present the section is left empty N/A Key interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Dose, timing, and cycling trace to the ER Therapeutic Protocol/Discontinuation sections.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Standard Dose, Timing, Cycling cover the key actionable aspects.
10.3 If less than three distinct actionable aspects are mentioned, unused sets are left empty and made invisible. N/A Three distinct actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three action cells populated with ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Anxiety Reduction, Cognitive Effects, Acute Calming from ER line 330.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Anxiety (best-supported) first, then cognitive, then acute calming.
11.3 If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible. N/A Three distinct time-to-effect aspects are present.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All three time cells populated from ER content.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Mirrors the ER Expected Benefits tiers.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four variables present.
12.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. 🟢 Benefit names only; supporting detail stripped.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 Only the ER’s integral heading parenthetical “(nootropic effect)” retained; no effect sizes/samples/studies.
12.5 If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. 🟢 benefits_high hidden with display:none; no empty-state text.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Mirrors the ER Potential Risks tiers.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four variables present.
13.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. 🟢 Risk names only; detail stripped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 Only the ER’s integral heading parenthetical “(intranasal route)” retained; no frequencies/grades/studies.
13.5 If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. 🟢 risks_high and risks_medium hidden with display:none; no empty-state text.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Table and cadence trace to the ER Monitoring Protocol.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 hs-CRP, Fasting glucose, Fasting insulin, Lipid panel all listed with targets.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Cadence matches ER line 356.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Drawn from the ER qualitative markers (lines 367–371).
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five qualitative markers listed.

Issues 02/07/2026 02:27

Pass rate 100.00%. No issues found.